BOSTON, April 2, 2008 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services organization, today announced that Larry Ereshefsky, Pharm.D., F.C.C.P., B.C.C.P., and Malek Bajbouj, M.D., have been appointed as Vice Presidents of Clinical Pharmacology Consulting Services in the Company's international clinical pharmacology business. These leading experts advise clients on early phase clinical development in the central nervous system (CNS) therapeutic area, including in regard to psychiatry, neuropsychopharmacology, and neurophysiology clinical studies. Dr. Ereshefsky is based at PAREXEL's Clinical Pharmacology Research Unit in Los Angeles, California in the United States and Dr. Bajbouj is based at the unit in Berlin, Germany.
"Clients increasingly rely on our experts to help identify and select the most promising compounds in the Phase I and Proof of Concept stages. These decisions are based on demonstrating safety and signals of efficacy as early as possible in the drug development process," said Herman Scholtz, M.D., Corporate Vice President and Worldwide Head, Clinical Pharmacology, PAREXEL. "We expect that the extensive medical and scientific expertise Dr. Ereshefsky and Dr. Bajbouj bring to our clinical pharmacology business will further strengthen our central nervous system capabilities in order to help biopharmaceutical companies address growing complexity in this important area of early phase clinical development."
Dr. Larry Ereshefsky is Board Certified in Psychiatric Pharmacy, and
has more than 28 years of experience in the neuropsychopharmacology and
psychiatry fields. His expertise includes all phases of clinical research
and psychopharmacological ev
|SOURCE PAREXEL International Corporation|
Copyright©2008 PR Newswire.
All rights reserved